https://www.selleckchem.com/mTOR.html
Results The sensitivity of the assay was 97.73% (95% CI 96,23-99,24) and the clinical specificity, 99.33% (95% CI 98,88-99,78) while the efficacy and the accuracy were 98.96%. Conclusions Our results show that the new solid phase of UMELISA CHAGAS® can be used for immunodiagnostic, blood certification, and epidemiological surveillance in endemic and non-endemic countries with high-risk populations. Malaria is a vector-borne disease widely distributed in the Amazon region and the coastal area of northern Ecuador. Its epidemiology involves related fa
Curtir
Comentario
Compartilhar
